No 1 source of global mining news and opinion
BHP Group said on Tuesday its first-half underlying profit was largely unchanged from a year ago, citing strong revenue generation, but warned of higher costs from the lagged effect of global inflation persisting into the second-half.
BHP remained cautious on top commodity consumer China until it became clearer as to how effective its stimulus policies push will be, while noting a “more balanced” demand picture in India which has shown “continued healthy momentum.” However, it predicted a “more balanced global economy and evidence that the worst of the general inflationary wave is behind us, will have a positive impact on our industry in calendar year 2024.”
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Rio Tinto, BHP tie up in Australian steel decarbonisation pilotNo 1 source of global mining news and opinion
Read more »
Andy Kim sinks first lady Tammy Murphy in NJ Senate race’s first Democratic conventionHis victory shows he can get support of the rank-and-file Democrats he'll need to overcome Tammy Murphy's advantages.
Read more »
Hot 100 First-Timers: BossMan Dlow Scores His First Chart Hit With ‘Get In With Me’BossMan Dlow debuts on the Hot 100 with 'Get In With Me.' Get the details.
Read more »
Stock futures are little changed after Dow tops 38,000 for the first time: Live updatesWall Street is coming off a notable trading session for the major averages, with the Dow Jones Industrial Average hitting 38,000 for the first time ever.
Read more »
First-Ever CRISPR-Based Therapy Approved for Sickle Cell DiseaseU.S. patients with sickle cell disease now have a novel treatment option: the first-ever CRISPR-based therapy.for use in patients age 12 years and older. In addition to offering hope of relief for people with severe forms of the painful blood disorder, the treatment, called Casgevy, is the world’s first to genetically tweak cells using theAnother gene therapy for sickle cell disease, called Lyfgenia and developed by biotech company bluebird bio, based in Somerville, Mass., was also approved December 8. Getting a green light for the first CRISPR-based medicine is exciting, says David Altshuler, chief scientific officer at Boston-based Vertex Pharmaceuticals, which developed the drug in a joint venture with CRISPR Therapeutics, a company in Cambridge, Mass. But the fact that the drug fills an unmet need for underserved patients is “more compelling to me, personally, than the fact that it’s CRISPR.” , most of them Black or Latino, have sickle cell disease. It is caused by a genetic defect in hemoglobin, the oxygen-carrying protein in red blood cells
Read more »
CBS New York Book Club's First Readers' Choice for 2024CBS New York readers have chosen 'Where You End' by Abbott Kahler as the first Readers' Choice for 2024. The book is about a woman with amnesia who uncovers her dangerous past with the help of her identical twin. Join the Book Club to read along and discuss.
Read more »